ISCF Application of whole Genome Sequencing approaches to Cancer - Webcast recording and slides now available
Posted on 30/10/2019
Innovate UK, part of UK Research and Innovation, will invest up to £5.4 million of the Industrial Strategy Challenge Fund as part of the Data to Early Diagnosis and Precision Medicine Challenge.
Applications can be made for both feasibility and collaborative projects lasting up to 18 months and with maximum eligible costs of £1m.
The aim of this competition, which closes on 22 January is to support projects that use whole genome sequencing to analyse cancers. This can be through the manipulation of existing whole genome data, through the collection of new sequence data or through a combination of both.
Possible approaches include but are not limited to:
• the development of new analytical or reporting tools for clinical decision support
• the identification of molecular signatures that allow for new or improved targeting of therapies
• the identification of new therapeutic targets
• new genetic signatures that can be used clinically, such as markers that support repurposing of drugs or a personalised approach to patient management
• the comparative assessment of alternative assay methods in parallel with whole genome sequencing
Applications that apply other forms of genetic analysis, including gene panels or arrays, in isolation will not be eligible for funding.
View and download the slides here.
You can view the full competition page here.
Click here to find out more about this event.
Guidance for applicants to work with the Experimental Cancer Medicine Centres (ECMC):
In relation to this competition, the ECMC’s precision medicine working group (PMWG) will conduct an internal shortlisting process, independent from Innovate UK, for companies that wish to partner with the network. The shortlisting meeting will take place before the Innovate UK deadline. Please note that the deadline to submit outlines is 5th December. To find out more please click here.